MAP2K7 and colorectal carcinoma: Since only ~ 3% of CRCs have mutant KRAS (G12C), therapeutic inhibitors of MEK (or ERK) downstream of KRAS/BRAF are essentially the only available RAS pathway targeted agents for a great majority of KRAS-mutated CRC patients.